Fast Five Quiz: Acute Lymphoblastic Leukemia (ALL) Management

Karen Seiter, MD


August 20, 2021

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults. In the United States alone, approximately 5930 cases of ALL were newly diagnosed in 2019, and nearly 1500 patients died of the disease in that same year. In developed countries, ALL is associated with a 5-year survival of 30%-45%. ALL is characterized by chromosomal abnormalities and genetic alterations involved in the increased proliferation and decreased differentiation of lymphoid precursor cells. Seventy-five percent of cases in adults develop from precursors of the B-cell lineage, with the remainder of cases involving malignant T-cell precursors. Despite a high rate of response to induction chemotherapy, only 30%-40% of adults with ALL will achieve long-term remission. Accurate assessment of prognosis, selection of the most appropriate initial treatment regimens, and identification of potential candidates for allogeneic stem cell transplant are key to achieving optimal outcomes for patients with ALL.

How familiar are you with updated strategies for the management of patients with ALL? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: